Head-to-head · free
Thermo Fisher Scientific vs First Tracks Biotherapeutics Inc
TMO vs TRAX — return on capital, cash generation, margins and balance sheet side by side.
TMO
1 / 2
measures where TMO leads
TRAX
1 / 2
measures where TRAX leads
A simple count of which company scores better on each measure — not a recommendation to buy or sell.
| Measure | TMO · FY2025 | TRAX |
|---|---|---|
| Revenue | $44.6B | — |
| Net income | $6.7B | — |
| Revenue growth (yearly, multi-year) | 3.2% | — |
| Free cash flow | $6.3B | — |
| Free cash flow margin | 14.1% | — |
| Net cash / (debt) | — | — |
| ROIC | 8.3% | — |
| Return on equity | 13.0% | -40.9% |
| Gross margin | 40.9% | — |
| Operating margin | 18.2% | — |
| Net debt / EBITDA | 2.81x | 0.69x |
Figures are as reported by each company; latest fiscal year shown.
Where Thermo Fisher Scientific's cash went (FY2025)
- Capital spending
- $1.5B
- Buybacks
- —
- Dividends
- —
- Acquisitions
- —
- Net debt issued / (repaid)
- —
Ask which business is stronger
"Which one reinvests at higher returns?" "Who carries more risk in its filings?" Get answers drawn straight from both companies' filings.
Compare them free